Article Information
History
- June 24, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Shuo Feng, PhD1,
- Daniel J. Phillips, MMath1,
- Thomas White, PhD4,
- Homesh Sayal, PhD4,
- Parvinder K. Aley, PhD1,
- Sagida Bibi, PhD1,
- Christina Dold, PhD1,
- Michelle Fuskova, MSc2,
- Sarah C. Gilbert, FMedSci3,
- Ian Hirsch, PhD4,
- Holly E. Humphries, PhD5,
- Brett Jepson, MS4,
- Elizabeth J. Kelly, PhD4,
- Emma Plested1,
- Kathryn Shoemaker, MS4,
- Kelly M. Thomas, PhD5,
- Johan Vekemans, PhD4,
- Tonya L. Villafana, PhD4,
- Teresa Lambe, PhD3,*,
- Andrew J Pollard, FMedSci1,2,*,
- Merryn Voysey, DPhil1,2,*,&,
- the Oxford COVID Vaccine Trial Group
- 1Oxford Vaccine Group, Department of Paediatrics, University of Oxford, UK
- 2NIHR Oxford Biomedical Centre, Oxford, UK
- 3The Jenner Institute, Nuffield Department of Medicine, University of Oxford, UK
- 4AstraZeneca PLC
- 5National Infection Service, Public Health England, Salisbury, UK
- ↵&Corresponding author: Merryn Voysey merryn.voysey{at}paediatrics.ox.ac.uk, Oxford Vaccine Group, Department of Paediatrics, University of Oxford, CCVTM, Churchill Road, Churchill Hospital, Oxford OX3 7LE United Kingdom
↵* Contributed Equally
Posted June 24, 2021.
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
